The blood protein, the preparation manner, contains manner, and the aforementioned protein which the aforementioned protein and the tPA inhibiter atsusei are done the medicine manufacture study constituent

摘要

The invention relates to a novel blood protein, called plasminogen activator binding protein (PA-BP), having a molecular mass of about 100,000 as determined by gel chromatography on Ultrogel ACA 44, an electrophoretic mobility in agarose at pH 8.6 equal to that of plasma beta -globulins, and an isoelectric point of 6.5-7.0. …??The protein binds specifically and reversibly to tissue type plasminogen activator (t-PA) and to urokinase in the presence of a free active centre and specific kringle 2 of t-PA, is thermostable up to at least 56 DEG C, and is cleared from the circulation with a half-life in the order of days. …??Further, the invention relates to methods for preparing the novel protein and to methods for assaying PA-BP, optionally in the presence of PA. …??As PA-BP was found to control the availability of t-PA and urokinase by reversible binding of plasminogen activators, the novel protein may be used in therapy. Consequently, the invention relates to pharmaceutical compositions containing PA-BP.